Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. 2015

Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
Department of Toxicology, Faculty of Pharmacy, Jagiellonian University, Medical College, Kraków, Poland.

The pathophysiology of psychiatric diseases, including depression, anxiety, schizophrenia and autism, is far from being fully elucidated. In recent years, a potential role of the oxidative stress has been highlighted in the pathogenesis of neuropsychiatric disorders. A body of clinical and preclinical evidence indicates that psychiatric diseases are characterized by higher levels of oxidative biomarkers and with lower levels of antioxidant defense biomarkers in the brain and peripheral tissues. In this article, we review current knowledge on the role of the oxidative stress in psychiatric diseases, based on clinical trials and animal studies, in addition, we analyze the effects of drug-induced modulation of oxidative balance and explore pharmacotherapeutic strategies for oxidative stress reduction.

UI MeSH Term Description Entries
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D001007 Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS. Angst,Anxiousness,Hypervigilance,Nervousness,Social Anxiety,Anxieties, Social,Anxiety, Social,Social Anxieties
D001321 Autistic Disorder A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-V) Autism, Infantile,Kanner's Syndrome,Autism,Autism, Early Infantile,Disorder, Autistic,Disorders, Autistic,Early Infantile Autism,Infantile Autism,Infantile Autism, Early,Kanner Syndrome,Kanners Syndrome
D001523 Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function. Mental Illness,Psychiatric Diseases,Psychiatric Disorders,Psychiatric Illness,Behavior Disorders,Diagnosis, Psychiatric,Mental Disorders, Severe,Psychiatric Diagnosis,Illness, Mental,Mental Disorder,Mental Disorder, Severe,Mental Illnesses,Psychiatric Disease,Psychiatric Disorder,Psychiatric Illnesses,Severe Mental Disorder,Severe Mental Disorders
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
June 2020, Journal of affective disorders,
Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
April 1992, The Journal of nervous and mental disease,
Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
December 2019, Neuroscience research,
Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
June 2007, CNS & neurological disorders drug targets,
Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
July 2009, Drug discovery today,
Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
January 2020, Oxidative medicine and cellular longevity,
Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
January 2021, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
January 2015, Behavioural brain research,
Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
November 2010, International journal of psychiatry in clinical practice,
Irena Smaga, and Ewa Niedzielska, and Maciej Gawlik, and Andrzej Moniczewski, and Jan Krzek, and Edmund Przegaliński, and Joanna Pera, and Małgorzata Filip
July 1979, The American journal of orthopsychiatry,
Copied contents to your clipboard!